

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Island with limited liability)

(Stock Code: 1228)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) is pleased to announce that Dr. Hu Lan (“**Dr. Hu**”) has been appointed as an Independent Non-executive Director of the Company and a member of the remuneration committee of the Board (the “**Remuneration Committee**”) with effect from February 16, 2022.

Hu Lan

Dr. Hu, aged 53, has over 18 years of experience in healthcare investment, operations and administrative management. She served as the investment manager of JP Morgan Chase Bank from August 2002 to March 2004. She founded Beijing Amcare Women’s & Children’s Hospital Co., Ltd. (北京美中宜和婦兒醫院有限公司) in June 2004 and has been its director, chairman of the board and general manager. Since 2013, she has been the member of the 12th and 13th Beijing Municipal Committee of the Chinese People’s Political Consultative Conference. She is currently serving as the chairman of the board and general manager of Beijing Amcare Medical Management Co., Ltd. (北京美中宜和醫療管理(集團)有限公司), the chairman of the board of Beijing Meizhong Airui Tumor Hospital Co., Ltd. (北京美中愛瑞腫瘤醫院有限責任公司), the independent director of Beijing Yida Shidai Technology Development Co., Ltd. (北京醫大時代科技發展有限公司) and the executive director and general manager of Beijing Xuanhe Yazhi Management Consulting Co., Ltd. (北京軒和雅致管理諮詢有限公司). She obtained a bachelor’s degree in medicine from Peking University in 1993. She further obtained a Ph.D. in medical sciences from Northeast Ohio Medical University in 2000 and a master’s degree in business administration from University of Michigan in 2002.

The Company and Dr. Hu entered into an appointment letter. The initial term of her appointment letter shall commence from February 16, 2022 for a period of three years (subject always to re-election as and when required under the Articles of Association) until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than one month’s prior notice in writing. Under the appointment letter, Dr. Hu will receive an annual director’s fee of US\$30,000. commencing on the effective date of her appointment.

As at the date of this announcement and save as disclosed above, Dr. Hu has not held any other directorship in any listed public companies in the past three years and does not have any interest in the shares of the Company within the meaning of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Dr. Hu does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder of the Company.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, nor are there any other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to offer Dr. Hu its sincere congratulations on her appointment as an Independent Non-executive Director of the Company.

CHANGES IN THE COMPOSITION OF BOARD COMMITTEES

The Board announces the following changes in the composition of various board committees of the Company, with effect from February 16, 2022:

- (1) Mr. James Arthur Geraghty (“**Mr. Geraghty**”) has ceased to be the member of the Remuneration Committee;
- (2) Dr. Richard James Gregory has ceased to be a member of the audit committee (the “**Audit Committee**”) of the Board; and
- (3) Mr. Geraghty was appointed as a member of the Audit Committee.

By Order of the Board of Directors
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, February 16, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Xiao Le as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Hu Lan as independent non-executive directors.